KSPI Investors Have Opportunity to Lead Joint Stock Company Kaspi.kz Securities Fraud Lawsuit Filed by The Rosen Law Firm

https://mma.prnewswire.com/media/2598307/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Joint Stock CompanyKaspi.kz (NASDAQ: KSPI) between January 19, 2024 and September 19, 2024, both dates inclusive (the “Class Period”), of the important February 18, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. So

BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit

https://mma.prnewswire.com/media/2598307/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ: BIOA) pursuant and/or traceable to the registration statement for BioAge's initial public offering conducted on September 26, 2024 (the “IPO”), of the important March 10, 2025 lead plaintiff deadline. So what: If you purchased BioAge

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities ofRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023 and October 30, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve

Independence Contract Drilling, Inc. Announces Emergence from Chapter 11 as a Private Company with Increased Liquidity and a Significantly Deleveraged Balance Sheet

Independence Contract Drilling, Inc. (the “Company” or “ICD”) today announced that it has successfully completed its Chapter 11 restructuring process and has emerged as a private company that is financially and operationally stronger and well-positioned for the future. ICD's Plan of Reorganization was confirmed by the Bankruptcy Court onJanuary 9, 2025. As a result of

ZHAOWEI Unveils Groundbreaking Dexterous Hand at CES 2025

CES 2025, held from January 7-10 at the Las Vegas Convention Center, once again solidified its role as the premier global platform for technological innovation, with ZHAOWEI (Shenzhen ZHAOWEI Machinery & Electronics Co., Ltd) making a strong impression. As a leading provider of intelligent robotics and high-performance motor solutions, ZHAOWEI showcased its groundbreaking Dexterous Hand,

Adjust brings two all-new adjustable vapes

— mysweet, industry's first to adjust sweetness — mysour unleashes four levels of sourness Adjust, avaping explorer, unveils mysweet and mysour, two adjustable single-use vapes for a tailored flavor experience in the US. As the latest additions to Adjust portfolio, mysweet and mysour embody the brand's signature versatility while spearheading the industry with four-tier sweetness

JELD-WEN Completes Sale of Towanda, PA Facility as a Result of Court-Ordered Divestiture Process

JELD-WEN Holding, Inc. (NYSE: JELD) (“JELD-WEN” or the “Company”), a leading global manufacturer of building products, today announced that, in compliance with the court-ordered divestiture of its Towanda, Pennsylvania business, JELD-WEN has completed its previously announced sale of Towanda to Woodgrain Inc. on January 17, 2025 for a purchase price of $115 million, subject to

Pyramid Consulting, Inc. Partners with Dynatrace to Provide Unified Observability, AIOps, and Application Security

Pyramid Consulting, Inc., a global leader in workforce and technology solutions, announces a transformative partnership with Dynatrace (NYSE: DT). The partnership establishes Pyramid Consulting, Inc., and its technology division, Celsior, as a premier Global Systems Integrator (GSI) for Dynatrace and enhances our capabilities to drive digital transformation and superior IT performance management for our clients

Health Canada Authorizes Vabysmo® (faricimab injection) Pre-Filled Syringe (PFS) for Three Leading Causes of Vision Loss

— Vabysmo PFS is the first and only syringe prefilled with a Health-Canada approved bispecific antibody to treat retinal conditions that can cause blindness1 — Designed to simplify administration, Vabysmo PFS provides retina specialists with a ready-to-use option — Vabysmo PFS will be available for people living with wet AMD, DME and RVO Hoffmann-La Roche

Scroll to Top